Humira gains psoriasis indication
The FDA has approved Humira (adalimumab, from Abbott) for the treatment of adults with moderate-to-severe chronic plaque psoriasis, who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate. The approval was based on two clinical trials which showed that nearly 3 in 4 patients achieved 75% clearance or better at week 16 of treatment versus placebo. Humira, a tumor necrosis factor-alpha blocker, is already indicated for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
For more information call (800) 633-9110 or visit www.humira.com.